693 related articles for article (PubMed ID: 35447302)
1. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections.
Taquet M; Dercon Q; Harrison PJ
Brain Behav Immun; 2022 Jul; 103():154-162. PubMed ID: 35447302
[TBL] [Abstract][Full Text] [Related]
2. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients.
Taquet M; Sillett R; Zhu L; Mendel J; Camplisson I; Dercon Q; Harrison PJ
Lancet Psychiatry; 2022 Oct; 9(10):815-827. PubMed ID: 35987197
[TBL] [Abstract][Full Text] [Related]
3. Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study.
Wu JT; La J; Branch-Elliman W; Huhmann LB; Han SS; Parmigiani G; Tuck DP; Brophy MT; Do NV; Lin AY; Munshi NC; Fillmore NR
JAMA Oncol; 2022 Feb; 8(2):281-286. PubMed ID: 34854921
[TBL] [Abstract][Full Text] [Related]
4. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records.
Taquet M; Geddes JR; Husain M; Luciano S; Harrison PJ
Lancet Psychiatry; 2021 May; 8(5):416-427. PubMed ID: 33836148
[TBL] [Abstract][Full Text] [Related]
5. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
6. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
Sacco C; Del Manso M; Mateo-Urdiales A; Rota MC; Petrone D; Riccardo F; Bella A; Siddu A; Battilomo S; Proietti V; Popoli P; Menniti Ippolito F; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M;
Lancet; 2022 Jul; 400(10346):97-103. PubMed ID: 35780801
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
[TBL] [Abstract][Full Text] [Related]
9. Post-COVID conditions following COVID-19 vaccination: a retrospective matched cohort study of patients with SARS-CoV-2 infection.
Malden DE; Liu IA; Qian L; Sy LS; Lewin BJ; Asamura DT; Ryan DS; Bezi C; Williams JTB; Kaiser R; Daley MF; Nelson JC; McClure DL; Zerbo O; Henninger ML; Fuller CC; Weintraub ES; Saydah S; Tartof SY
Nat Commun; 2024 May; 15(1):4101. PubMed ID: 38778026
[TBL] [Abstract][Full Text] [Related]
10. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
Nordström P; Ballin M; Nordström A
Lancet Infect Dis; 2022 Jun; 22(6):781-790. PubMed ID: 35366962
[TBL] [Abstract][Full Text] [Related]
11. Vaccination and the risk of post-acute sequelae after COVID-19 in the Omicron-predominant period.
Huh K; Kim YE; Bae GH; Moon JY; Kang JM; Lee J; Bae JW; Peck KR; Jung J
Clin Microbiol Infect; 2024 May; 30(5):666-673. PubMed ID: 38331252
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis.
Efe C; Taşçılar K; Gerussi A; Bolis F; Lammert C; Ebik B; Stättermayer AF; Cengiz M; Gökçe DT; Cristoferi L; Peralta M; Massoumi H; Montes P; Cerda E; Rigamonti C; Yapalı S; Adali G; Çalışkan AR; Balaban Y; Eren F; Eşkazan T; Barutçu S; Lytvyak E; Zazueta GM; Kayhan MA; Heurgue-Berlot A; De Martin E; Yavuz A; Bıyık M; Narro GC; Duman S; Hernandez N; Gatselis NK; Aguirre J; Idilman R; Silva M; Mendizabal M; Atay K; Güzelbulut F; Dhanasekaran R; Montano-Loza AJ; Dalekos GN; Ridruejo E; Invernizzi P; Wahlin S
J Autoimmun; 2022 Oct; 132():102906. PubMed ID: 36088883
[TBL] [Abstract][Full Text] [Related]
13. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study.
Chia PY; Ong SWX; Chiew CJ; Ang LW; Chavatte JM; Mak TM; Cui L; Kalimuddin S; Chia WN; Tan CW; Chai LYA; Tan SY; Zheng S; Lin RTP; Wang L; Leo YS; Lee VJ; Lye DC; Young BE
Clin Microbiol Infect; 2022 Apr; 28(4):612.e1-612.e7. PubMed ID: 34826623
[TBL] [Abstract][Full Text] [Related]
14. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
Front Immunol; 2022; 13():940562. PubMed ID: 36091023
[TBL] [Abstract][Full Text] [Related]
15. Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study.
Cohen K; Ren S; Heath K; Dasmariñas MC; Jubilo KG; Guo Y; Lipsitch M; Daugherty SE
BMJ; 2022 Feb; 376():e068414. PubMed ID: 35140117
[TBL] [Abstract][Full Text] [Related]
16. Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection.
Liu B; Gidding H; Stepien S; Cretikos M; Macartney K
Vaccine; 2022 Oct; 40(43):6288-6294. PubMed ID: 36180375
[TBL] [Abstract][Full Text] [Related]
17. Associations between COVID-19 vaccination and incident psychiatric disorders after breakthrough SARS-CoV-2 infection: The VENUS Study.
Murata F; Maeda M; Murayama K; Nakao T; Fukuda H
Brain Behav Immun; 2024 Mar; 117():521-528. PubMed ID: 38355026
[TBL] [Abstract][Full Text] [Related]
18. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
[TBL] [Abstract][Full Text] [Related]
19. Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination.
Butt AA; Nafady-Hego H; Chemaitelly H; Abou-Samra AB; Khal AA; Coyle PV; Kanaani ZA; Kaleeckal AH; Latif AN; Masalmani YA; Bertollini R; Raddad LJA
Int J Infect Dis; 2021 Sep; 110():353-358. PubMed ID: 34375762
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
